Skip to main content

Advertisement

SpringerLink
Log in

P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

BMS-387032, a novel cyclin-dependent kinase 2 inhibitor, is currently in phase I clinical trials for anticancer therapy. The oral bioavailability of BMS-387032 has been found to be about 31% in rats. Absorption and first-pass metabolism were evaluated as possible reasons for the incomplete oral bioavailability in rats.

Methods

Male Sprague-Dawley rats were given single doses of BMS-387032 intraarterially (9.1 mg/kg), orally (9.1 mg/kg), or intraportally (10 mg/kg). The routes of excretion of BMS-387032 after intravenous dosing were investigated in bile-duct-cannulated rats. The rate of metabolism of BMS-387032 was investigated in liver microsomes. The permeability of BMS-387032 was evaluated using Caco-2 cells, an in vitro model of the intestinal epithelium. To determine if BMS-387032 was a P-glycoprotein substrate, brain uptake studies were conducted in P-glycoprotein knockout versus wildtype mice.

Results

The exposure in rats after an intraportal dose was similar to that after an intraarterial dose, indicating that absorption may play a greater role than liver first-pass metabolism in the low oral bioavailability seen in rats. After an intravenous dose, the percent of dose excreted unchanged in the urine and bile over a 9-h period was 28% and 11%, respectively. In vitro studies in rat liver microsomes showed low rates of metabolism of BMS-387032. The Caco-2 cell permeability of BMS-387032 was <15 nm/s in the apical to basolateral direction, and 161 nm/s in the basolateral to apical direction, indicating that it may be a substrate for an intestinal efflux transporter. A P-glycoprotein binding assay showed that BMS-387032 might be a P-glycoprotein modulator. Brain penetration studies in mice showed brain levels of BMS-387032 about 3.5-fold higher in P-glycoprotein knockout mice than in wildtype mice, providing evidence of BMS-387032 being a P-glycoprotein substrate.

Conclusions

Poor absorption may be playing a greater role than extensive first-pass metabolism in the incomplete oral bioavailability of BMS-387032 seen in rats. The efflux transporter, P-glycoprotein, may be responsible for limiting absorption, as BMS-387032 appears to be a substrate of P-glycoprotein.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361–398

    Article  CAS  PubMed  Google Scholar 

  2. Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–1095

    Article  CAS  PubMed  Google Scholar 

  3. Dey S, Ramachandra M, Pastan I, Gottesman MM, Ambudkar SV (1998) Photoaffinity labeling of human P-glycoprotein: effect of modulator interaction and ATP hydrolysis on substrate binding. Methods Enzymol 292:318–328

    CAS  PubMed  Google Scholar 

  4. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Dekker, New York

    Google Scholar 

  5. Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385–427

    Article  CAS  PubMed  Google Scholar 

  6. Hidalgo IJ, Raub TJ, Borchardt RT (1989) Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96:736–749

    CAS  PubMed  Google Scholar 

  7. Hunter T, Pines J (1994) Cyclins and cancer. II. Cyclin D and CDK inhibitors come of age. Cell 79:573–582

    Article  CAS  PubMed  Google Scholar 

  8. Kim KS, Kimball SD, Misra RN, Rawlins DB, Hunt JT, Xiao HY, Lu S, Qian L, Han WC, Shan W, Mitt T, Cai ZW, Poss MA, Zhu H, Sack JS, Tokarski JS, Chang CY, Pavletich N, Kamath A, Humphreys WG, Marathe P, Bursuker I, Kellar KA, Roongta U, Batorsky R, Mulheron JG, Bol D, Fairchild CR, Lee FY, Webster KR (2002) Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities. J Med Chem 45:3905–3927

    Article  CAS  PubMed  Google Scholar 

  9. Mandagere AK, Thompson TN, Hwang KK (2002) Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. J Med Chem 45:304–311

    Article  CAS  PubMed  Google Scholar 

  10. Meunier V, Bourrie M, Berger Y, Fabre G (1995) The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications. Cell Biol Toxicol 11:187–194

    CAS  PubMed  Google Scholar 

  11. Misra RN, Xiao HY, Kim KS, Lu S, Han WC, Barbosa SA, Hunt JT, Rawlins DB, Shan W, Ahmed SZ, Qian L, Chen BC, Zhao R, Bednarz MS, Kellar KA, Mulheron JG, Batorsky R, Roongta U, Kamath A, Marathe P, Ranadive SA, Sack JS, Tokarski JS, Pavletich NP, Lee FY, Webster KR, Kimball SD (2004) N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J Med Chem 47:1719–1728

    Article  Google Scholar 

  12. Pines J (1994) The cell cycle kinases. Semin Cancer Biol 5:305–313

    CAS  PubMed  Google Scholar 

  13. Pines J (1995) Cyclins, CDKs and cancer. Semin Cancer Biol 6:63–72

    Article  CAS  PubMed  Google Scholar 

  14. Raucy JL, Lasker JM (1991) Isolation of P450 enzymes from human liver. Methods Enzymol 206:577–587

    Article  CAS  PubMed  Google Scholar 

  15. Schinkel AH, Smit JJM, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood–brain barrier and to increased sensitivity to drugs. Cell 77:491–502

    Article  CAS  PubMed  Google Scholar 

  16. Schinkel AH, Wagenaar E, Mol CAAM, van Deemter L (1996) P-glycoprotein in the blood–brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517–2524

    CAS  PubMed  Google Scholar 

  17. Senderowicz AM (2003) Small-molecule cyclin-dependent kinase modulators. Oncogene 22:6609–6620

    Article  CAS  PubMed  Google Scholar 

  18. Silverman JA (1999) Multidrug-resistance transporters. Pharm Biotechnol 12:353–386

    CAS  PubMed  Google Scholar 

  19. Tanigawara Y (2000) Role of P-glycoprotein in drug disposition. Ther Drug Monit 22:137–140

    Article  CAS  PubMed  Google Scholar 

  20. van Asperen J, Mayer U, van Tellingen O, Beijnen JH (1997) The functional role of P-glycoprotein in the blood–brain barrier. J Pharm Sci 86:881–884

    Article  PubMed  Google Scholar 

  21. Wacher VJ, Salphati L, Benet LZ (2001) Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev 46:89–102

    Article  CAS  PubMed  Google Scholar 

  22. Webster KR (2000) Therapeutic potential of targeting the cell cycle. Chem Res Toxicol 13:940–943

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The assistance of the Technical Support Unit in animal maintenance, dosing, and sample collection, and the assistance of Grace Lee and J.B. Akinsanya in LC/MS/MS analysis and Haiyang Zhang in metabolite elucidation is greatly appreciated. We thank Sandra Dando and Anthony Marino for conducting the Caco-2 cell experiments, and Laishun Chen for conducting the P-glycoprotein photoaffinity assay.

Author information

Authors and Affiliations

  1. Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research Institute, P.O. Box 4000, Princeton, NJ 08543, USA

    Amrita V. Kamath, Saeho Chong, Ming Chang & Punit H. Marathe

Authors
  1. Amrita V. Kamath
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Saeho Chong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ming Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Punit H. Marathe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amrita V. Kamath.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kamath, A.V., Chong, S., Chang, M. et al. P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats. Cancer Chemother Pharmacol 55, 110–116 (2005). https://doi.org/10.1007/s00280-004-0873-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-004-0873-3

Keywords

Search

Navigation